Cagriniltide: Mechanism of Action
$75.60 · Lot COA published · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY
Buy Cagriniltide Peptide 10mg (Cagrilintide)Mechanism of Action
Cagriniltide functions as a non-selective dual agonist of both calcitonin receptors (CTR) and amylin receptors (AMY1R, AMY2R, AMY3R) — heterodimers of CTR with RAMPs 1, 2, or 3.[3][12]
Receptor Targets & Binding
| Target | Interaction | Evidence |
|---|---|---|
| Calcitonin Receptor (CTR) | Non-selective agonist; class B1 GPCR; EC50 62 pM | Kruse et al. (2021); Cao et al. (2025) cryo-EM[3][9] |
| AMY1R (CTR+RAMP1) | Potent agonist; "bypass" conformation binding | RAMP1/3 KO abolishes the anorectic response (mice)[8] |
| AMY3R (CTR+RAMP3) | Potent agonist; EC50 49 pM (hAMY3R) | Carvas et al. (2025): required for the response in mice[8][13] |
| CGRPR / AM1R / AM2R | No or very low activity — selective for amylin/calcitonin axis | Fletcher et al. (2021)[12] |
Downstream Signaling
| Pathway | Effect | Consequence |
|---|---|---|
| Gs / Adenylyl Cyclase / cAMP | Gs-protein activation → adenylyl cyclase → intracellular cAMP accumulation | Primary signaling cascade for satiety[9] |
| Neuronal cFos (AP/NTS/LPBN) | Induces cFos expression in area postrema, nucleus of solitary tract, lateral parabrachial nucleus | Satiety signaling; 57% fewer AP neurons in RAMP1/3 KO[8] |
| Gastric Emptying | Delays gastric emptying | Gastric-emptying endpoints |
| Glucagon Suppression | Suppresses postprandial glucagon from pancreatic α-cells | Pancreatic signaling endpoints[6] |
Unique Binding Characteristics
| Property | Cagriniltide | Salmon Calcitonin |
|---|---|---|
| Receptor Conformation | "Bypass" (stabilized by ionic lock N14E–V17R) | "CT-like" conformation |
| Residence Time | 3–6 minutes (rapid dissociation) | 45–60 minutes (slow dissociation) |
| Desensitization | Prevents receptor downregulation | Causes receptor downregulation |
RAMP Dependence: Carvas et al. (2025) demonstrated that the food-intake responses to cagriniltide in mice are strictly dependent on AMY1R and AMY3R — knockout of RAMP1 and RAMP3 abolished the response, with 57% fewer neurons activated in the area postrema.[8]
Cryo-EM Structural Insights
Cao et al. (2025) and Gu et al. (2026) resolved the cagriniltide-bound calcitonin-receptor and amylin-receptor cryo-EM structures, revealing the distinct "bypass" binding conformation stabilized by the engineered N14E-V17R ionic lock. Unlike salmon calcitonin (which adopts a deep "CT-like" pose with prolonged residence time and progressive receptor desensitization), cagriniltide engages the receptor extracellular domain in a more shallow, dynamic geometry that produces full Gαs-coupled cAMP signaling but allows rapid dissociation. This kinetic difference is proposed as the molecular basis for maintained receptor responsiveness with repeat exposure rather than progressive downregulation.[9][10]
Hindbrain Satiety Circuitry
The principal central site of action is the area postrema (AP), a circumventricular organ outside the blood-brain barrier where AMY1R/AMY3R-expressing neurons project to the nucleus of the solitary tract (NTS) and the lateral parabrachial nucleus (LPBN). cFos mapping studies show robust neuronal activation across this AP→NTS→LPBN→hypothalamic axis after cagriniltide exposure; RAMP1/3 knockout eliminates 57% of AP cFos induction and abolishes the anorectic response — establishing AMY1R/AMY3R (rather than the calcitonin receptor in isolation) as the primary target.[8] Downstream effects include delayed gastric emptying, suppression of postprandial glucagon from pancreatic α-cells, and reduced caloric intake (-51% over 24 h in mouse food-intake studies at 30 nmol/kg).[6][8]
“Preclinical Research Summary Key Preclinical Studies StudyModelKey FindingsRef Carvas et al.”
References
- Enebo LB, et al. Lancet, 397(10286), 1736-1748, 2021.
- Lau DCW, et al. Lancet, 398(10317), 2160-2172, 2021.
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(15), 11183-11194, 2021.
- Frias JP, et al. Lancet, 402(10403), 720-730, 2023.
- Garvey WT, et al. New England Journal of Medicine, 393(7), 635-647, 2025.
- Davies MJ, et al. New England Journal of Medicine, 393(7), 648-659, 2025.
- Verma S, et al. Hypertension, 83(2), e26055, 2026.
- Carvas AO, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 118, 105836, 2025.
- Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, 3389, 2025.
- Gu YM, et al. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica, 47(1), 162-172, 2026.
- Wang Y, Feng Z, Yu L. The Innovation Medicine, 3(3), 100150, 2025.
- Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. JPET, 377(3), 417-440, 2021.
- Dahl K, et al. Journal of Medicinal Chemistry, 67(14), 11688–11700, 2024.
- Becerril S, Frühbeck G. Lancet, 397(10286), 1687-1689, 2021.
- D'Ascanio AM, et al. Cardiology in Review, 32(1), 83-90, 2024.
- Mikhail N, Wali S. Clinical Trials and Clinical Research, 2(5), 2023.
- Hales CM. New England Journal of Medicine, 393(7), 712-714, 2025.
- Gadde KM, Allison DB. Lancet, 398(10317), 2132-2134, 2021.
- Dehestani B, et al. Journal of Obesity & Metabolic Syndrome, 30(4), 320-325, 2021.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
Buy Cagriniltide Peptide 10mg (Cagrilintide)→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.
